{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:29:46Z","timestamp":1792178986392,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was funded by Johnson & Johnson."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction\/Objective<\/jats:title>\n            <jats:p>Oral glucocorticoids (OGC) are conventionally used as first-line treatment for dermatomyositis (DM) and polymyositis (PM). This study evaluated clinical and economic outcomes associated with long-term (LT) OGC use in DM\/PM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Adults with\u2009\u2265\u20092 medical claims of DM\/PM 30\u2012365\u00a0days apart from January 1, 2016, to December 31, 2022, and\u2009\u2265\u20091 diagnosis code of a physician specialty of interest were selected from the MarketScan Commercial and Medicare Supplemental databases. Patients should have\u2009\u2265\u20091 OGC pharmacy claim (i.e., date of first claim defined as index date) on or after the diagnosis date,\u2009\u2265\u200912\u00a0months pre- and post-index continuous enrollment, and no diagnosis of inclusion body myositis during the study. The LT group included patients with continuous OGC use for\u2009\u2265\u20093 consecutive months within the 12-month post-index period, whereas short-term (ST) users included those with\u2009&lt;\u20093 consecutive months of OGC use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Two thousand two-hundred eighty patients were included (LT, 1313 [57.6%]; ST, 967 [42.4%]). Compared with ST, LT OGC patients had significantly higher incidences of OGC-related complications, such as heart failure (adjusted odds ratio [aOR], 1.8; 95% CI, 1.3\u20122.7) and osteoporosis (aOR, 1.9; 95% CI, 1.4\u20122.6), after covariate adjustment. LT users had increased odds for both all-cause (aOR, 1.7; 95% CI, 1.3\u20122.2) and disease-related inpatient admission (aOR, 3.8; 95% CI, 2.3\u20126.2) versus ST users. Higher adjusted average annual all-cause (by US $30,555; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and disease-related costs (by US $21,311; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) were incurred by LT versus ST users.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>DM\/PM patients with LT OGC use had higher rates of associated medical conditions and higher healthcare resource utilization and costs than ST users.<\/jats:p>\n            <jats:p>\n              <jats:table-wrap>\n                <jats:table>\n                  <jats:tbody>\n                    <jats:tr>\n                      <jats:td align=\"left\" colspan=\"2\">Key points\u2022 Long-term use of oral glucocorticoids (OGC) in patients with dermatomyositis (DM) and polymyositis (PM) is associated with increased risk of complications, and there is limited real-world evidence on the association of long-term use with clinical and economic outcomes.\u2022 This real-world claims-based study demonstrated that long-term OGC use in patients with DM\/PM leads to higher rates of complications, advanced treatment use and healthcare resource utilization, and higher costs compared with short-term OGC use.\u2022 These findings highlight the limitations of OGC as a therapeutic tool and further support an unmet medical need for new treatment options among patients with DM\/PM.\u2022 Disease management with novel treatments that have an advantageous safety profile and can be utilized any\u00a0time throughout the disease course may provide safer, more efficacious alternatives to OGC.<\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody>\n                <\/jats:table>\n              <\/jats:table-wrap>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10067-025-07651-1","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:32:52Z","timestamp":1757457172000},"page":"4169-4178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term oral glucocorticoid use is associated with complications, healthcare resource utilization, and costs among patients with dermatomyositis or polymyositis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-8038","authenticated-orcid":false,"given":"Rohit","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Labson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Crivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Zazzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"7651_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/B978-0-323-98818-6.00023-6","volume":"195","author":"MC Dalakas","year":"2023","unstructured":"Dalakas MC (2023) Autoimmune inflammatory myopathies. Handb Clin Neurol 195:425\u2013460. https:\/\/doi.org\/10.1016\/B978-0-323-98818-6.00023-6","journal-title":"Handb Clin Neurol"},{"key":"7651_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1759720X11415306","volume":"3","author":"DJ Gazeley","year":"2011","unstructured":"Gazeley DJ, Cronin ME (2011) Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskelet Dis 3:315\u2013324. https:\/\/doi.org\/10.1177\/1759720X11415306","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7651_CR3","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/WCO.0000000000000855","volume":"33","author":"J Tanboon","year":"2020","unstructured":"Tanboon J, Uruha A, Stenzel W, Nishino I (2020) Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol 33:590\u2013603. https:\/\/doi.org\/10.1097\/WCO.0000000000000855","journal-title":"Curr Opin Neurol"},{"key":"7651_CR4","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","volume":"75","author":"K Mariampillai","year":"2018","unstructured":"Mariampillai K, Granger B, Amelin D et al (2018) Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 75:1528\u20131537. https:\/\/doi.org\/10.1001\/jamaneurol.2018.2598","journal-title":"JAMA Neurol"},{"key":"7651_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","volume":"19","author":"T Khoo","year":"2023","unstructured":"Khoo T, Lilleker JB, Thong BY, Leclair V, Lamb JA, Chinoy H (2023) Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol 19:695\u2013712. https:\/\/doi.org\/10.1038\/s41584-023-01033-0","journal-title":"Nat Rev Rheumatol"},{"key":"7651_CR6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mus.23302","volume":"45","author":"DE Furst","year":"2012","unstructured":"Furst DE, Amato AA, Iorga SR, Gajria K, Fernandes AW (2012) Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 45:676\u2013683. https:\/\/doi.org\/10.1002\/mus.23302","journal-title":"Muscle Nerve"},{"key":"7651_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-13-103","volume":"13","author":"KE Smoyer-Tomic","year":"2012","unstructured":"Smoyer-Tomic KE, Amato AA, Fernandes AW (2012) Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord 13:103. https:\/\/doi.org\/10.1186\/1471-2474-13-103","journal-title":"BMC Musculoskelet Disord"},{"key":"7651_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/rheumatology\/kew503","volume":"56","author":"J Svensson","year":"2017","unstructured":"Svensson J, Arkema EV, Lundberg IE, Holmqvist M (2017) Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology (Oxford) 56:802\u2013810. https:\/\/doi.org\/10.1093\/rheumatology\/kew503","journal-title":"Rheumatology (Oxford)"},{"key":"7651_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/pgmj.2005.038455","volume":"82","author":"AC Cordeiro","year":"2006","unstructured":"Cordeiro AC, Isenberg DA (2006) Treatment of inflammatory myopathies. Postgrad Med J 82:417\u2013424. https:\/\/doi.org\/10.1136\/pgmj.2005.038455","journal-title":"Postgrad Med J"},{"key":"7651_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/rheumatology\/41.1.7","volume":"41","author":"EH Choy","year":"2002","unstructured":"Choy EH, Isenberg D (2002) Treatment of dermatomyositis and polymyositis. Rheumatology 41:7\u201313. https:\/\/doi.org\/10.1093\/rheumatology\/41.1.7","journal-title":"Rheumatology"},{"key":"7651_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/09286586.2018.1513042","volume":"26","author":"VV Chirikov","year":"2019","unstructured":"Chirikov VV, Shah R, Kwon Y, Patel D (2019) Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: real-world data analysis. Ophthalmic Epidemiol 26:27\u201346. https:\/\/doi.org\/10.1080\/09286586.2018.1513042","journal-title":"Ophthalmic Epidemiol"},{"key":"7651_CR12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/MJT.0b013e3182987983","volume":"22","author":"T Mathur","year":"2015","unstructured":"Mathur T, Manadan AM, Thiagarajan S, Hota B, Block JA (2015) Corticosteroid monotherapy is usually insufficient treatment for idiopathic inflammatory myopathy. Am J Ther 22:350\u2013354. https:\/\/doi.org\/10.1097\/MJT.0b013e3182987983","journal-title":"Am J Ther"},{"key":"7651_CR13","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, Wan G, Nelson WW (2017) Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther 39:2216\u20132229. https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.011","journal-title":"Clin Ther"},{"key":"7651_CR14","doi-asserted-by":"publisher","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","volume":"52","author":"T Volmer","year":"2018","unstructured":"Volmer T, Effenberger T, Trautner C, Buhl R (2018) Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J 52:1800703. https:\/\/doi.org\/10.1183\/13993003.00703-2018","journal-title":"Eur Respir J"},{"key":"7651_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3899\/jrheum.101083","volume":"38","author":"S Bernatsky","year":"2011","unstructured":"Bernatsky S, Panopalis P, Pineau CA, Hudson M, St Pierre Y, Clarke AE (2011) Healthcare costs of inflammatory myopathies. J Rheumatol 38:885\u2013888. https:\/\/doi.org\/10.3899\/jrheum.101083","journal-title":"J Rheumatol"},{"key":"7651_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/mus.23384","volume":"46","author":"DE Furst","year":"2012","unstructured":"Furst DE, Amato AA, Iorga SR, Bancroft T, Fernandes AW (2012) Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population. Muscle Nerve 46:496\u2013505. https:\/\/doi.org\/10.1002\/mus.23384","journal-title":"Muscle Nerve"},{"key":"7651_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3111\/13696998.2016.1151433","volume":"19","author":"J Bradford Rice","year":"2016","unstructured":"Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M (2016) Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population. J Med Econ 19:649\u2013654. https:\/\/doi.org\/10.3111\/13696998.2016.1151433","journal-title":"J Med Econ"},{"key":"7651_CR18","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1177\/0961203318790675","volume":"27","author":"S Kabadi","year":"2018","unstructured":"Kabadi S, Yeaw J, Bacani AK, Tafesse E, Bos K, Karkare S, DeKoven M, Vina ER (2018) Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus. Lupus 27:1799\u20131809. https:\/\/doi.org\/10.1177\/0961203318790675","journal-title":"Lupus"},{"key":"7651_CR19","doi-asserted-by":"publisher","unstructured":"Butler AM, Nickel KB, Overman RA, Brookhart MA (2021) IBM MarketScan research databases. In: Sturkenboom M, Schink T (eds) Databases for pharmacoepidemiological research. Springer Series on Epidemiology and Public Health, Springer, Cham, pp 243\u2013251. https:\/\/doi.org\/10.1007\/978-3-030-51455-6_20","DOI":"10.1007\/978-3-030-51455-6_20"},{"key":"7651_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","volume":"15","author":"SA Greenberg","year":"2019","unstructured":"Greenberg SA (2019) Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 15:257\u2013272. https:\/\/doi.org\/10.1038\/s41584-019-0186-x","journal-title":"Nat Rev Rheumatol"},{"key":"7651_CR21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1185\/03007995.2013.818531","volume":"29","author":"O Ethgen","year":"2013","unstructured":"Ethgen O, de Lemos EF, Bruyere O, Reginster JY (2013) What do we know about the safety of corticosteroids in rheumatoid arthritis? Curr Med Res Opin 29:1147\u20131160. https:\/\/doi.org\/10.1185\/03007995.2013.818531","journal-title":"Curr Med Res Opin"},{"issue":"733\u2013740","key":"7651_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.074","volume":"78","author":"SH Yu","year":"2018","unstructured":"Yu SH, Drucker AM, Lebwohl M, Silverberg JI (2018) A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol 78(733\u2013740):e711. https:\/\/doi.org\/10.1016\/j.jaad.2017.09.074","journal-title":"J Am Acad Dermatol"},{"key":"7651_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12016-015-8511-x","volume":"52","author":"E Tiniakou","year":"2017","unstructured":"Tiniakou E, Mammen AL (2017) Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol 52:20\u201333. https:\/\/doi.org\/10.1007\/s12016-015-8511-x","journal-title":"Clin Rev Allergy Immunol"},{"key":"7651_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010111","volume":"12","author":"AH Opinc","year":"2022","unstructured":"Opinc AH, Makowska JS (2022) Update on malignancy in myositis-well-established association with unmet needs. Biomolecules 12:111. https:\/\/doi.org\/10.3390\/biom12010111","journal-title":"Biomolecules"},{"key":"7651_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1203475416665601","volume":"21","author":"JK Qiang","year":"2017","unstructured":"Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg 21:131\u2013136. https:\/\/doi.org\/10.1177\/1203475416665601","journal-title":"J Cutan Med Surg"},{"key":"7651_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.nmd.2015.04.013","volume":"25","author":"NE Johnson","year":"2015","unstructured":"Johnson NE, Arnold WD, Hebert D et al (2015) Disease course and therapeutic approach in dermatomyositis: a four-center retrospective study of 100 patients. Neuromuscul Disord 25:625\u2013631. https:\/\/doi.org\/10.1016\/j.nmd.2015.04.013","journal-title":"Neuromuscul Disord"},{"key":"7651_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/acr.24498","volume":"74","author":"F Espinosa-Ortega","year":"2022","unstructured":"Espinosa-Ortega F, Holmqvist M, Dastmalchi M, Lundberg IE, Alexanderson H (2022) Factors associated with treatment response in patients with idiopathic inflammatory myopathies: a registry-based study. Arthritis Care Res (Hoboken) 74:468\u2013477. https:\/\/doi.org\/10.1002\/acr.24498","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"7651_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-11-143","volume":"11","author":"XM Shu","year":"2011","unstructured":"Shu XM, Lu X, Xie Y, Wang GC (2011) Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China. BMC Neurol 11:143. https:\/\/doi.org\/10.1186\/1471-2377-11-143","journal-title":"BMC Neurol"},{"key":"7651_CR29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon DH, Glynn RJ, Karlson EW et al (2020) Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med 172:369\u2013380. https:\/\/doi.org\/10.7326\/M19-3369","journal-title":"Ann Intern Med"},{"issue":"766\u2013774","key":"7651_CR30","doi-asserted-by":"publisher","first-page":"e761","DOI":"10.1053\/j.gastro.2013.06.009","volume":"145","author":"J Panes","year":"2013","unstructured":"Panes J, Lopez-Sanroman A, Bermejo F et al (2013) Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn\u2019s disease. Gastroenterology 145:766\u2013774.e1. https:\/\/doi.org\/10.1053\/j.gastro.2013.06.009","journal-title":"Gastroenterology"},{"key":"7651_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222\u2013233. https:\/\/doi.org\/10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"key":"7651_CR32","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s40744-023-00566-w","volume":"10","author":"HA Stirnadel-Farrant","year":"2023","unstructured":"Stirnadel-Farrant HA, Golam SM, Naisbett-Groet B, Gibson D, Langham J, Langham S, Samnaliev M (2023) Adverse outcomes, healthcare resource utilization, and costs associated with systemic corticosteroid use among adults with systemic lupus erythematosus in the UK. Rheumatol Ther 10:1167\u20131182. https:\/\/doi.org\/10.1007\/s40744-023-00566-w","journal-title":"Rheumatol Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07651-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07651-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07651-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:25:31Z","timestamp":1760365531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07651-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7651"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07651-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RA has served as a consultant for Alexion, ANI Pharmaceuticals, argenx, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cabaletta Bio, Capella BioScience, Capstan, Corbus, CSL Behring, EMD Serono, Galapagos, Horizon Therapeutics, I-Cell, Immunovant, Janssen, Kezar, Kyverna, Lilly, Merck, Novartis, Nuvig Therapeutics, Octapharma, Pfizer, Roivant, Sanofi, and Teva; has received grant\/research support from Boehringer Ingelheim, EMD Serono, Johnson & Johnson, Mallinckrodt, and Pfizer, and Q32; and has served in advisory boards for Johnson & Johnson. QC is a former employee of Johnson & Johnson. DL, CC, and FZ are employees and shareholders of Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}